Primer on Tumor Immunology and Cancer Immunotherapy™

Primer on Tumor Immunology and Cancer Immunotherapy™

A Pre-Conference Program; additional registration fee applies 

The understanding of cancer immunobiology has increased dramatically in recent years, leading to the successful development of novel immune-based treatment options to improve cancer patient outcomes. The SITC Primer on Tumor Immunology and Cancer Immunotherapy™ is designed to provide a foundation for understanding core immunology principles as they relate to basic and clinical research in immunotherapy of cancer. New this year, the Primer on Tumor Immunology and Cancer Immunotherapy™ will also touch on emerging therapies and technologies to ensure attendees at all levels stay updated in our expanding field, while also laying a comprehensive foundational base for all SITC 2020 attendees.

Tuesday, Nov. 10, 2020*

*Dates and times subject to change. 

Program Organizers

  • Michael A. Curran, PhD – The University of Texas MD Anderson Cancer Center
  • Yvonne Saenger, MD – Columbia University Irving Medical Center 

Program Schedule*

*Program schedule subject to change. 

Introduction
Michael A. Curran, PhD – The University of Texas MD Anderson Cancer Center
Session I: Generating Anti-Tumor Immunity
Adaptive Immunity to Tumors and Cytokines: Laying the Foundation for Immunotherapy
Jonathan D. Powell, MD, PhD – Johns Hopkins University School of Medicine
Antigen Presenting Cells
Elizabeth M. Jaffee, MD – Sidney Kimmel Cancer Center, Johns Hopkins University
Suppressive Myeloid Cells
Dmitry I. Gabrilovich, MD, PhD – AstraZeneca
Session I Panel Discussion - Session I Speakers
Break
Session II: Approaches to Immunotherapy I
Introduction
Michael A. Curran, PhD – The University of Texas MD Anderson Cancer Center
T cell checkpoint blockade/costimulation
Cancer Vaccination
Ugur Sahin, MD - BioNTech Group
Myeloid Activation
Michael A. Curran, PhD – The University of Texas MD Anderson Cancer Center
Session II Panel Discussion - Session II Speakers 
Lunch
Session III: Approaches to Immunotherapy II
Introduction
Yvonne Saenger, MD – Columbia University Irving Medical Center
Adoptive T/NK cell Therapy 
Chrystal M. Paulos, PhD – Emory University
Metabolic Modification of the TME
Greg M. Delgoffe, PhD – University of Pittsburgh

Biospecific antibodies
John R. Desjarlais, PhD – Xencor, Inc.
Session III Panel Discussion - Session III Speakers
Break
Session IV: Clinical Practice of Immunotherapy
Introduction
Yvonne Saenger, MD – Columbia University Irving Medical Center

Biomarkers and correlatives
Yvonne Saenger, MD – Columbia University Irving Medical Center

Immune Related Adverse Events
Michael A. Postow, MD – Memorial Sloan Kettering Cancer Center 

Session IV Panel Discussion - Session IV Speakers
Closing Remarks


Target Audience

The target audience for this annual, one-day educational program includes students, postdoctoral fellows and technicians from academia and industry, as well as physicians and scientists at more senior levels who wish to solidify their understanding of tumor immunology and immunotherapy, pharmacists and registered nurses.

Learning Objectives

At the conclusion of this activity, participants should be able to:

  • Describe the key principles of tumor immunology and immunotherapy
  • Review current approaches to immunotherapy including immune checkpoint modulation, activation of myeloid cells, modulation of tumor metabolism, T/NK cell adoptive transfer and bispecific antibodies
  • Outline immune monitoring techniques as well as biomarker strategies and their role in trial design and patient selection
  • Enhance scientific exchange with colleagues and collaborators on research and application of cancer immunotherapies to improve outcomes of patients with cancer

Continuing Education

This program will be accredited to offer CME, CNE, CPE and MOC credits.


Jointly_Accredited_Provider_Logo.jpg

SITC_Primer_2019.jpg
SITC_2019_Primer_2.jpg